Through our network of global connections, we aim to make knowledge not just available, but valuable. We want to help you acquire expertise that can be directly applied to your practice. Explore the various medical education resources below:
EHA-SWG Scientific meeting on Immunotherapy: Checkpoint inhibition in hematologi...
Selected from the latest EHA-SWG Scientific Meeting on Immunotherapy, we present two lectures covering the use of immune checkpoint inhibitors (ICIs) in hematology. Peter Brossart explains the mechanism of action of these drugs and Paul Bröckelmann gives an updated overview of approved and emerging indications.
A Primer on CAR-T Therapy: What Does It Mean for Pathologists?: A Summary Guidan...
The College of American Pathologists Personalized Health Care Committee developed a summary guidance paper to educate pathologists on CAR-T and chimeric antigen receptor-derived cellular therapy, provide a better understanding of their role in this process, explain important regulatory aspects of CAR-T therapy, and advocate for pathologist involvement in the delivery and monitoring of CAR-based treatment.
Lymphodepletion optimization for CAR T-cell therapy
At the 8th annual meeting of the Society of Hematologic Oncology (SOHO), Elizabeth Budde presented how the process of lymphodepletion can be optimized to aid persistence and efficacy of infused CAR T-cells.
2nd European CAR T Cell Meeting (Jan 30 - Feb 1, 2020) Report
Sections: (1) The clinical landscape for CAR-T, and current developments in Europe, (2) The global efforts to improve CAR T-cell therapy and (3) Regulatory considerations and directions for the European CAR-T landscape
Is there an optimal time to deploy immunotherapies in multiple myeloma?
During the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the Multiple Myeloma Hub spoke to Meral Beksaç, Ankara University School of Medicine, Ankara, TR, about immunotherapy for MM: Is there an optimal time to deploy immunotherapies in multiple myeloma?
How I treat relapsed acute lymphoblastic leukemia in the pediatric population
Immunotherapy changed the therapeutic landscape of children with relapsed ALL. Several cases highlighting contemporary treatment decision-making are presented in this educational paper.
EHA CAR-T Course: Processes in CAR-T
"Processes in CAR-T" - the third CAR-T course within EHA's new immunotherapy program is now freely accessible via the EHA Campus. This course addresses processes involved in the manufacture of CAR T-cells from apheresis to treatment, as well as the role of different team members including pharmacists and nurses. It also includes considerations specific to pediatric patients.
ERIC 2020 | Developing T-cell based therapies for CLL treatment
Arnon Kater, MD, PhD, University of Amsterdam, Amsterdam, The Netherlands, discusses T-cell based therapy to treat chronic lymphocytic leukemia (CLL).
IACH Focus on Leukemia 2020 | Antibody-based therapy to treat AML: radioimmunoco...
Farhad Ravandi, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the use of antibody-based therapy in acute myeloid leukemia (AML).
Exploring the Future of CAR T-Cell Therapy in Multiple Myeloma
C. Ola Landgren, MD, PhD, chief of Myeloma Service and hematologic oncologist at Memorial Sloan Kettering Cancer Center, discusses what is next for chimeric antigen receptor (CAR) T-cell therapy in the multiple myeloma landscape.